1. Introduction {#sec1-ijms-19-03378}
===============

Despite advances in the treatment of patients with advanced clear-cell renal cell carcinoma (ccRCC) with anti-angiogenic agents, checkpoint inhibitors, and mammalian target of rapamycin (mTOR) inhibitors alone and in combination, durable responses are seen in about 30% of treated ccRCC patients \[[@B1-ijms-19-03378],[@B2-ijms-19-03378],[@B3-ijms-19-03378],[@B4-ijms-19-03378],[@B5-ijms-19-03378],[@B6-ijms-19-03378],[@B7-ijms-19-03378],[@B8-ijms-19-03378],[@B9-ijms-19-03378],[@B10-ijms-19-03378],[@B11-ijms-19-03378],[@B12-ijms-19-03378],[@B13-ijms-19-03378]\]. A systematic review of the first line for metastatic renal carcinoma reported an average progression-free survival of 8.4 months with a range of 6.5 to 12.3 months, and an average overall survival of 24.4 months with a range of 18.5 to 32.9 months \[[@B14-ijms-19-03378]\]. Based on the clinical data generated in patients with advanced cancer, resistance and the associated dose-limiting toxicities remain major clinical challenges. There is an unmet clinical need to identify a new treatment modality that is patient-centric, selective, and efficacious for metastatic ccRCC patients. Both primary and metastatic ccRCC tumors are uniquely characterized by the expression of altered biomarkers associated with increased angiogenesis, metastasis, and drug resistance, including deletion and/or mutation of the von Hippel--Lindau (VHL) tumor suppressor gene in the majority of ccRCC tumors, resulting in the stable expression of hypoxia-inducible factors 1α and 2α (HIFs), and vascular endothelial growth factor (VEGF) \[[@B15-ijms-19-03378],[@B16-ijms-19-03378],[@B17-ijms-19-03378],[@B18-ijms-19-03378],[@B19-ijms-19-03378],[@B20-ijms-19-03378],[@B21-ijms-19-03378],[@B22-ijms-19-03378],[@B23-ijms-19-03378],[@B24-ijms-19-03378],[@B25-ijms-19-03378],[@B26-ijms-19-03378],[@B27-ijms-19-03378],[@B28-ijms-19-03378],[@B29-ijms-19-03378],[@B30-ijms-19-03378],[@B31-ijms-19-03378],[@B32-ijms-19-03378],[@B33-ijms-19-03378]\]. Programmed death 1 (PD-1) is expressed in the membrane and cytoplasm of activated T cells, B cells, and dendritic cells. Programmed death ligand 1 (PD-L1) is expressed in 21--75% of ccRCC tumors, and allows cancer cells to evade immune response \[[@B34-ijms-19-03378],[@B35-ijms-19-03378],[@B36-ijms-19-03378],[@B37-ijms-19-03378],[@B38-ijms-19-03378],[@B39-ijms-19-03378],[@B40-ijms-19-03378],[@B41-ijms-19-03378],[@B42-ijms-19-03378],[@B43-ijms-19-03378],[@B44-ijms-19-03378],[@B45-ijms-19-03378],[@B46-ijms-19-03378],[@B47-ijms-19-03378]\]. Although multiple signaling and epigenetic pathways regulate the expression of PD-L1, interferons γ and α (INF-γ and INF-α) and specific oncogenic micro RNAs (miRNAs) are also known to induce PD-L1 \[[@B48-ijms-19-03378],[@B49-ijms-19-03378],[@B50-ijms-19-03378],[@B51-ijms-19-03378],[@B52-ijms-19-03378],[@B53-ijms-19-03378]\]. PD-L1 incidence and intensity vary among different tumor types. The analysis of melanoma tumors revealed that 38% of them express both PD-L1 and tumor-infiltrating lymphocyte (TIL), while 41% are negative for both, and 1% are PD-L1-positive, and 20% are TIL-positive \[[@B38-ijms-19-03378],[@B54-ijms-19-03378],[@B55-ijms-19-03378]\]. PD-L1 was expressed in 69 out of 98 (70.9%) ccRCC tumors expressing mutant VHL. In all wild-type VHL tumors, 11.2% express PD-L1 \[[@B16-ijms-19-03378]\]. HIFs and PD-L1 are co-expressed in cancer cells. Under hypoxic conditions, HIFs regulate the expression of PD-L1 by binding to the hypoxia response element in the PD-L1 proximal promoter to activate its transcription \[[@B47-ijms-19-03378],[@B48-ijms-19-03378],[@B56-ijms-19-03378]\]. PD-L1 expression in cancer cells may, therefore, be regulated transcriptionally by HIF and post-transcriptionally by miRNAs. It is likely that the effective downregulation of HIFs would lead to the downregulation of PD-L1, resulting in an increased tumor response to subsequent treatment with anti-PD-1/PD-L1 therapies.

Thymidine phosphorylase (TP), an angiogenic protein and an enzyme required for the activation of several 5-fluorouracil (FU) prodrugs, is overexpressed by approximately 30--40% of cancers \[[@B57-ijms-19-03378],[@B58-ijms-19-03378],[@B59-ijms-19-03378],[@B60-ijms-19-03378],[@B61-ijms-19-03378],[@B62-ijms-19-03378],[@B63-ijms-19-03378]\]. TP may function as an independent prognostic factor for increased tumor vascularity, and a target for the activation of 5-FU prodrugs. Utilizing TP to activate 5-FU prodrugs may also reduce its angiogenic activity, and may synergize with VEGF-targeting drugs. The reported overexpression of TP in ccRCC provided the opportunity to evaluate 5-FU prodrugs, such as S-1, in combination with tyrosine kinase inhibitors (TKIs) targeting VEGF/VEGF receptor (VEGFR).

Morphologically, ccRCC tumors are characterized by extensive lipid accumulation. Hypoxia-inducible protein 2 (HIG-2) is highly expressed in tumors expressing HIF1α, but not HIF2α \[[@B22-ijms-19-03378],[@B64-ijms-19-03378]\]. Results generated indicate that HIG-2 is a direct target of HIF1α, but not HIF2α**.** Carnitine palmitoyltransferase (CPT1A), a fatty-acid transporter in the mitochondria, was recently reported to be a direct target of HIFs \[[@B65-ijms-19-03378]\]. Clear-cell RCC cells transfected with VHL led to the downregulation of CPT1A, resulting in fatty-acid transport into the mitochondria, and forcing the formation of lipid droplets from fatty acids. Recent published reports indicated that ccRCC tumor cells expressing mutant VHL and the stable expression of HIFs participate in lipid deposition. However, HIF2α, but not HIF1α, controls the expression of perilipin 2, resulting in lipid storage \[[@B66-ijms-19-03378]\]. In cells with a co-expression of HIFs, miRNA-155, and miRNA-210, it is possible that HIG-2, CPT1A, and perilipin 2 may also be regulated by miRNAs through HIF-dependent or -independent pathways. Since both HIFs are involved in the regulation of lipid droplets in ccRCC, agents that target HIF2α, but not HIF1α, may express limited antitumor activity. Agents that target both HIFs may have greater therapeutic impact and could avoid the need to regulate or target individual pathways regulated by HIFs.

2. Results {#sec2-ijms-19-03378}
==========

2.1. Hypoxia-Inducible Factors 1α and 2α (HIFs) and VHL Tumor Suppressor Gene {#sec2dot1-ijms-19-03378}
-----------------------------------------------------------------------------

The molecular profiles of ccRCC tumors are summarized in [Figure 1](#ijms-19-03378-f001){ref-type="fig"} and [Table 1](#ijms-19-03378-t001){ref-type="table"}. HIFs are transcriptional factors that regulate the expression of over 200 genes involved in angiogenesis, tumor metastasis, and drug resistance. Unlike colorectal and head-and-neck tumors, ccRCC tumors feature a high incidence and intensity of constitutively expressed HIFs, as well as lower levels of VEGF and prolyl hydroxylase 2 (PHD2), with no detectable prolyl hydroxylase 3 (PHD3), as assessed by immunohistochemistry ([Table 1](#ijms-19-03378-t001){ref-type="table"}).

Our laboratory was the first to report that constitutively expressed HIF1α and HIF2α ([Table 1](#ijms-19-03378-t001){ref-type="table"}, [Figure 2](#ijms-19-03378-f002){ref-type="fig"}) are selenium targets (adopted from References \[[@B20-ijms-19-03378],[@B32-ijms-19-03378]\]). The data in [Figure 2](#ijms-19-03378-f002){ref-type="fig"} show that the inhibition of constitutively expressed HIF1α and HIF2α in RC2 and 786.0 Clear-cell RCC cells, and HIF1α in FaDu head and neck \[[@B32-ijms-19-03378]\], A548 lung carcinoma cells, and HT29 colorectal tumor cells is selenium dose-dependent and independent of the disease site/cell type. Unlike other HIF-targeting agents, selenium inhibits HIF expression via PHD-dependent degradation \[[@B20-ijms-19-03378],[@B32-ijms-19-03378]\].

2.2. Tumor Vasculature {#sec2dot2-ijms-19-03378}
----------------------

To accommodate survival, growth, and metastasis, tumor cells promote the formation and development of new blood vessels \[[@B36-ijms-19-03378],[@B39-ijms-19-03378]\]. Tumor-associated blood vessels within the tumor microenvironment are unstable and leaky, and they could represent a barrier to the delivery of effective therapies to tumor cells \[[@B67-ijms-19-03378],[@B68-ijms-19-03378]\]. Thus, for the development of efficacious therapy, treatment should include drugs targeting biomarkers that induce the normalization of tumor-associated vasculature. Our laboratory was the first to report that the stabilization of tumor vasculature by MSC is dose- and schedule-dependent. We previously reported that the therapeutic dose and schedule of MSC/SLM exert dual effects. Firstly, anti-angiogenic effects were achieved via the inhibition of new vessel formation and a reduction in microvessel density. Secondly, tumor vascular maturation was achieved through an increase in pericyte recruitment. Collectively, these effects were associated with an increase in drug delivery and distribution to tumor cells. As shown in [Figure 3](#ijms-19-03378-f003){ref-type="fig"}, in vivo treatment with therapeutic doses of MSC resulted in a selective increase in vascular maturation index in tumors, but not in normal liver mouse tissues. The data generated demonstrate that tumor cells and their associated vasculature can be successfully and selectively modulated in vivo by a therapeutic, non-toxic dose and schedule of MSC. These results are consistent with the data generated by Jain et al., demonstrating normalization of the tumor microenvironment by Avastin, an anti-angiogenic agent \[[@B69-ijms-19-03378]\].

2.3. Oncogenic miRNA-155 and miRNA-210 {#sec2dot3-ijms-19-03378}
--------------------------------------

Non-coding miRNAs are small molecules involved in the post-transcriptional regulation of genes, and are often associated with increased angiogenesis and drug resistance. Micro RNAs function as either tumor suppressors or promoters, and they act by targeting the 3' untranslated region (3'-UTR) of targeted genes \[[@B71-ijms-19-03378],[@B72-ijms-19-03378]\]. Micro RNAs reduce the gene expression of mRNAs by inhibiting translation or via degradation of the transcript. Oncogenic miRNA-155 and miRNA-210 are highly overexpressed in ccRCC tumors expressing HIF1α, HIF2α, VEGF, and PD-L1 \[[@B73-ijms-19-03378],[@B74-ijms-19-03378],[@B75-ijms-19-03378],[@B76-ijms-19-03378],[@B77-ijms-19-03378],[@B78-ijms-19-03378],[@B79-ijms-19-03378],[@B80-ijms-19-03378],[@B81-ijms-19-03378]\].

To identify a possible link between HIF-α protein expression levels and tumor-associated miRNAs, three primary ccRCC biopsies and two ccRCC cell lines expressing a similar incidence and distribution of HIF-α were analyzed using a microarray for miRNA expression. Microarray analysis using an Exiqon microarray chip of RC2 cells treated with methylselenic acid (MSA), an inhibitor of HIF1α, revealed that 28 miRNAs were downregulated and 12 miRNAs were upregulated ([Figure 4](#ijms-19-03378-f004){ref-type="fig"}A). Although several miRNAs were altered, selected miRNAs which were upregulated and downregulated by MSA treatment are shown in [Figure 4](#ijms-19-03378-f004){ref-type="fig"}B. These results suggest that these miRNAs are likely regulated by HIF1α and can be effectively modulated by therapeutic doses of selenium.

The data in [Figure 5](#ijms-19-03378-f005){ref-type="fig"} indicate that the miRNAs that were significantly altered by MSA treatment of RC2 cells expressing HIF1α and of 786.0 cells expressing HIF2α were also altered in primary ccRCC biopsies.

Two miRNAs, Let-7b, and -328, which were upregulated, and miRNA-106b, -155, and -210, which were downregulated by MSA treatment of RC2 and 786.0 cells, were randomly selected to perform qRT-PCR analysis along with four primary ccRCC tumor biopsies and their paired normal kidney cells.

The results presented in [Figure 5](#ijms-19-03378-f005){ref-type="fig"} confirmed the microarray data that these selected miRNAs which were altered in RC2 and 786.0 cells were similarly altered in the patient biopsies, and their expressions could be modulated in vitro and in vivo by selenium. Collectively, the data generated demonstrate that a defined dose and schedule of selenium can effectively modulate the expression levels of specific oncogenic and tumor-suppressor miRNAs altered in ccRCC tumor cells.

2.4. Selenium: A Selective Modulator of Anticancer Therapies {#sec2dot4-ijms-19-03378}
------------------------------------------------------------

### 2.4.1. Nude Mice Bearing HIF1α {#sec2dot4dot1-ijms-19-03378}

The data in [Figure 6](#ijms-19-03378-f006){ref-type="fig"}A demonstrate the antitumor activity of MSC in sequential combination with two representative cytotoxic drugs, irinotecan (an approved drug for the treatment of colorectal cancer) and docetaxel (used in head-and-neck cancers among others), and radiation therapy. Oral daily administration of 10 mg/kg/day MSC for seven days prior to and concurrent with the administration of cytotoxic or radiation therapies beginning on day seven was associated with enhanced therapeutic efficacy.

The data in [Figure 6](#ijms-19-03378-f006){ref-type="fig"}B demonstrate the antitumor activity of MSC in sequential combination with radiation therapy of mice bearing A549 lung carcinoma tumors expressing HIF. Collectively, MSC was found to significantly enhance the therapeutic efficacy of chemotherapy and radiation in different human cancer xenografts from different disease sites. The results generated suggest that the action of selenium in tumor cells expressing HIFs is a universal phenomenon, irrespective of the cancer type or disease site.

### 2.4.2. Nude Mice Bearing Tumor Xenografts That Constitutively Expressed HIF2α {#sec2dot4dot2-ijms-19-03378}

[Figure 7](#ijms-19-03378-f007){ref-type="fig"}A,B depict tumor growth inhibition by MSC, SLM, axitinib, sunitinib, and topotecan. The dose and schedule of MSC and SLM that inhibited HIF exhibited limited but similar tumor growth inhibition. Sunitinib exerted greater antitumor activity than Avastin, axitinib, and topotecan \[[@B83-ijms-19-03378]\]. The order of antitumor activity is sunitinib \> Avastin ≥ axitinib \> topotecan \> MSC or SLM. The data in [Figure 7](#ijms-19-03378-f007){ref-type="fig"}C depict the antitumor activity of tyrosine kinase inhibitors (TKIs) that target VEGF/VEGFR, and topotecan alone and in combination with either MSC or SLM. The combination of topotecan and sunitinib in sequential combination with MSC or SLM had the most therapeutic efficacy and achieved long-term and durable responses not observed with these drugs administered individually. The data in [Figure 7](#ijms-19-03378-f007){ref-type="fig"}D indicate that MSC and SLM similarly potentiate the antitumor activity of axitinib, a Food and Drug Administration (FDA)-approved VEGFR-targeting agent for the treatment of relapsed ccRCC patients. The data in [Figure 7](#ijms-19-03378-f007){ref-type="fig"}E confirm that HIFs are a critical therapeutic target of MSC. MSC potentiates the antitumor activity of topotecan, a topoisomerase 1 poison which targets HIF synthesis, as well as that of Avastin, axitinib, and sunitinib, which target VEGF/VEGFR. In comparison, the antitumor activity of irinotecan, a topoisomerase 1 poison with no demonstrable effects on HIF protein expression, was not potentiated by MSC. In this model, S-1 exhibited significant antitumor activity, perhaps due to overexpression of TP. Collectively, the data in [Figure 7](#ijms-19-03378-f007){ref-type="fig"}E indicate that optimal therapeutic benefit was obtained with MSC in sequential combination with topotecan and sunitinib.

3. Discussion {#sec3-ijms-19-03378}
=============

Clear-cell RCCs and their associated microenvironment express a unique molecular and morphological profile including a variety of tumor-suppressor and oncogenic miRNAs. However, miRNA-155 and miRNA210 are extensively characterized and overexpressed in multiple tumor types \[[@B75-ijms-19-03378],[@B76-ijms-19-03378],[@B77-ijms-19-03378],[@B78-ijms-19-03378]\]. Although VHL may be regulated by multiple biomarkers expressed in tumor cells and their adjacent microenvironment, miRNA-155 and -210 emerged as key modulators of VHL function, and may offer an alternative mechanism for stable expression of HIFs in ccRCC tumors \[[@B17-ijms-19-03378],[@B77-ijms-19-03378]\]. Loss of VHL in ccRCC tumors may mimic the upregulation of HIFs by hypoxia. In recognition of the critical role of VHL in the pathogenesis of ccRCC tumors, efforts are underway to develop anti-VHL chemical agents \[[@B84-ijms-19-03378],[@B85-ijms-19-03378]\]. Similarly, recognizing that HIFs are upregulated by hypoxia-dependent and -independent pathways and that they are critical therapeutic targets, a number of HIF inhibitors are presently under preclinical and clinical development. A recent phase 1 clinical trial of PT2385, a synthetic small-molecule HIF2α antagonist, demonstrated clinical activity in previously treated ccRCC patients \[[@B86-ijms-19-03378]\].

Tumor microarray analysis demonstrated that HIF1α and HIF2α are individually and jointly co-expressed in a majority of primary and metastatic ccRCC biopsies \[[@B20-ijms-19-03378]\]. In addition, it was reported that, although HIF1α and HIF2α are structurally similar, they functionally regulate different target genes in different cell types \[[@B25-ijms-19-03378]\]. Furthermore, under hypoxia, the expression of VEGF is regulated by HIF1α, but not by HIF2α \[[@B33-ijms-19-03378]\]. It is possible that the inhibition of one HIF isoform may induce the activation of the other in support of tumor growth. The data to date suggest that optimal therapeutic benefit may require targeting both HIF1α and HIF2α.

HIFs and PD-L1 are co-expressed in cancer cells. Under hypoxic conditions, HIFs regulate the expression of PD-L1 by binding to the hypoxia response element in the PD-L1 proximal promoter to activate its transcription \[[@B42-ijms-19-03378],[@B47-ijms-19-03378]\]. PD-L1 expression in cancer cells may, therefore, be regulated transcriptionally by HIF and post-transcriptionally by miRNAs. It is likely that effective downregulation of HIFs would lead to the downregulation of PD-L1, resulting in an increased tumor response to subsequent treatment with anti-PD-1/PD-L1 therapies.

Micro RNA-155 and miRNA-210, amongst others, were reported to modulate the tumor microenvironment \[[@B74-ijms-19-03378],[@B75-ijms-19-03378]\], regulate glucose metabolism \[[@B87-ijms-19-03378]\], and target transcription factor E2F2 in ccRCC tumor cells \[[@B88-ijms-19-03378]\]. Neal et al. reported that the VHL/HIF axis regulates the expression of several types of miRNAs in ccRCC tumors, including miRNA155 and miRNA-210 \[[@B53-ijms-19-03378]\]. Increasing evidence suggests that oncogenic miRNA-155 and miRNA-210 are regulators of immune response biomarkers, including forkhead box P3 (FoxP3) regulatory T cell, myeloid-derived suppressor cell (MDSC) T-cells, and immune checkpoint PD-1/PD-L1 \[[@B56-ijms-19-03378],[@B80-ijms-19-03378],[@B81-ijms-19-03378],[@B89-ijms-19-03378],[@B90-ijms-19-03378]\]. Despite the progress made in our understanding of the biology and therapeutic potential of miRNAs, their clinical use as a prognostic and as a predictor of therapeutic outcome is yet to be determined. Efforts to develop miRNA inhibitors fall short of clinical expectations \[[@B91-ijms-19-03378],[@B92-ijms-19-03378],[@B93-ijms-19-03378]\]. The limited clinical benefits were attributed, in part, to their limited bioavailability, instability, and dose-limiting toxicities, in addition to an inability to demonstrate in vivo modulation of expression of intended targets. Our laboratory was the first to demonstrate that specific types, doses, and a schedule of MSC in ccRCC xenograft models can selectively modulate specific types of miRNAs.

Clear-cell RCC tumors are highly vascular with clear, large cytoplasms expressing perilipin 2, hypoxia-inducible lipid-droplet protein 2, which represses fatty-acid metabolism, and is a target gene of HIF1α \[[@B22-ijms-19-03378],[@B64-ijms-19-03378],[@B65-ijms-19-03378]\]. Molecularly, the majority of ccRCC tumors express high incidence and intensity of HIF1α, HIF2α, and oncogenic miRNA-155 and -210, which target genes involved in ccRCC tumorigenesis, including VEGF and PD-L. The tumor microenvironment associated with ccRCC is leaky and unstable, expressing the common biomarkers that regulate tumor cell growth and metastasis commonly seen in many cancers. Thus, ccRCC tumors provide the opportunity to test the hypothesis and rationale for a mechanism-based treatment combination with selenium that may offer the potential for the development of novel treatment in patients with ccRCC and other cancers with similar expression of Se targets.

Resistance and dose-limiting toxicities continue to represent major clinical challenges for both cytotoxic chemotherapy and biological targeted therapies. In general, in vivo resistance is regulated by multiple molecular and immunological biomarkers expressed in tumor cells and their surrounding microenvironment. These two tumor compartments are functionally interactive. The tumor microenvironment could promote tumor growth while impeding optimal drug delivery and the distribution of effective tumor drug concentrations. Thus, the tumor microenvironment may be considered as the gatekeeper, while tumor cells are the ultimate targets. In order to achieve durable antitumor activity, treatment should include a combination of drugs that enable targeting both the tumor microenvironment and the tumor cells.

In ccRCC, HIFs, miRNA-155, and miRNA-210 are commonly co-expressed and were reported earlier to regulate the expression of gene targets implicated in enhanced angiogenesis, tumor metastasis, and resistance. While considerable efforts are underway to develop miRNA- and HIF-based strategies, in vivo toxicity, tumor instability, and limited drug delivery in effective concentrations continue to plague efforts to have a more clinically effective outcome \[[@B93-ijms-19-03378]\]. In addition, an increased activation of 5-FU prodrugs by TP should result in increased antitumor activity \[[@B94-ijms-19-03378],[@B95-ijms-19-03378],[@B96-ijms-19-03378]\].

During the last several years, our laboratory determined that SLM, an FDA-approved drug for clinical trials, and MSC (under development) exert several effects that are not shared by other selenium compounds and HIF-targeting compounds that are currently under preclinical and clinical evaluation \[[@B20-ijms-19-03378],[@B23-ijms-19-03378],[@B70-ijms-19-03378],[@B83-ijms-19-03378],[@B84-ijms-19-03378],[@B85-ijms-19-03378],[@B86-ijms-19-03378],[@B87-ijms-19-03378],[@B88-ijms-19-03378],[@B89-ijms-19-03378],[@B90-ijms-19-03378]\]. We were the first to demonstrate \[[@B97-ijms-19-03378],[@B98-ijms-19-03378]\], in several tumor xenograft models, that (1) therapeutic and nontoxic doses and a schedule of organic selenium compounds, SLM and MSC, potently enhance constitutively expressed HIF1α and HIF2α degradation; (2) SLM and MSC downregulate VEGF, which is regulated by HIF1α, but not by HIF2α; (3) SLM and MSC stabilize tumor vasculature resulting in the selective enhancement of drug delivery to tumor cells, consistent with results reported by Jain \[[@B69-ijms-19-03378]\]; (4) SLM and MSC modulate the expression of a number of tumor-suppressor and oncogenic miRNAs altered in ccRCC tumors; (5) SLM and MSC offer selective protection against toxicity induced by toxic and often lethal doses of cytotoxic drugs in preclinical models \[[@B83-ijms-19-03378]\]; and (6) treatment with MSC and SLM was associated with significant enhancement of the efficacy and selectivity of anticancer therapies in head-and-neck, colorectal, and renal cancer xenografts. The antitumor activity of VEFG/VEGFR-targeted therapies alone and in combination with topotecan and S-1 can be further enhanced by MSC in mice bearing VHL-deficient 786.0 ccRCC tumors expressing HIF2α, VEGF, miRNA-155, and miRNA-210. Taken together, non-toxic doses of selenium may offer the potential for the development of novel therapeutic modality. [Chart 1](#ijms-19-03378-ch001){ref-type="fig"} is an outline of the approach used in the translational development of selenium in combination with anticancer drugs in preclinical models to phase 1 and 2 clinical trials. The data generated in several xenograft models provided the rationale for the development of a phase 1 clinical trial in ccRCC patients. The aim was to confirm that the SLM dose used to yield blood selenium concentrations similar to those determined therapeutically, synergistic with anticancer drugs in the preclinical model, could be achieved clinically without toxicity. The optimal SLM dose defined in the phase 1 trial \[[@B99-ijms-19-03378]\] was used to design a phase 2 trial of SLM in sequential combination with axitinib, aimed at assessing the efficacy and modulation of relevant molecular correlates.

Based on the preclinical results generated, a mechanism-based combination therapy is proposed, as outlined in [Chart 2](#ijms-19-03378-ch002){ref-type="fig"}. In order to achieve optimal therapeutic benefit with the proposed mechanism-based drug combination, the dose, schedule, and sequence of MSC and SLM are critical parameters. Pretreatment with selenium prior to and concurrent with the administration of anticancer therapy is necessary for the optimal modulation of relevant selenium biomarkers in tumor cells and for the optimal stabilization of tumor vasculature. To maintain the optimal and sustained inhibition of HIFs and associated gene targets, it is recommended that topotecan be administered in combination with MSC or SLM. Since therapeutic doses and the schedule of selenium partially downregulate the expression levels of VEGF in tumor cells expressing HIF1α but not HIF2α \[[@B20-ijms-19-03378],[@B23-ijms-19-03378]\], we propose, therefore, adding TKI inhibitors to the combination regimen in order for maximum downregulation of VEGF/VEGFR. This proposed mechanism-based combination was evaluated in 786.0 xenografts and was determined to be highly selective and therapeutically effective. The dose and schedule of the SLM/MSC used were selected based on their molecularly effective dose instead of the maximum tolerated dose. Furthermore, since the expression level of PD-L1 is regulated by HIFs and miRNAs, it is reasonable to expect that SLM/MSC will also modulate the therapeutic efficacy of checkpoint inhibitors. Proof of principle in ccRCC could provide the basis for the verification of this mechanism-based treatment combination in other tumors expressing these molecular targets similarly affected by SLM/MSC.

4. Conclusions and Future Perspectives {#sec4-ijms-19-03378}
======================================

The aim of this paper was to determine that the levels of specific biomarkers altered in the majority of ccRCC tumors, such as HIFs, oncogenic miRNA-155 and miRNA-210, and VEGF, can be selectively downregulated by therapeutic nontoxic doses and a schedule of MSC and SLM. In addition, the aim was also to confirm that downregulation of these biomarkers would translate into therapeutic synergy with anticancer therapies. The results in several xenograft models and with multiple cytotoxic and biologic agents demonstrated that the dose- and time-dependent downregulation of constitutively expressed HIFs, miRNA-155 and -210, and VEGF-A by selenium was associated with enhanced therapeutic efficacy and selectivity of anticancer therapies. Preclinical data generated provided the rationale for the development of a phase 1 clinical trial in ccRCC patients treated with escalating doses of SLM in sequential combination with a fixed dose of axitinib \[[@B99-ijms-19-03378],[@B100-ijms-19-03378]\]. Unlike the 200 μg/day SLM dose used in prevention clinical trials, the SLM doses used in combination therapy were 10 mg/kg in nude mice, and 8000 μg/day in ccRCC patients, which was the dose recommended for the ongoing phase 2 clinical trial for efficacy assessment and for the monitoring of the effects of SLM on relevant biomarkers. The plasma selenium concentrations achieved clinically with the recommended SLM dose were comparable with those achieved with SLM doses determined therapeutically synergistic with anticancer drugs in preclinical models. The mechanism-based drug combination proposed in [Chart 2](#ijms-19-03378-ch002){ref-type="fig"} warrants expanded preclinical investigation and clinical verification. Proof of concept that enhanced therapeutic efficacy and selectivity of axitinib in refractory ccRCC patients are SLM dose- and schedule-dependent will be highly innovative and significant. Furthermore, the ability of selenium to downregulate specific biomarkers associated with drug resistance may provide the opportunity for the clinical development of SLM in sequential combination with other clinically available targeted therapies.

5. Material and Methods {#sec5-ijms-19-03378}
=======================

5.1. Cell Culture and Drug Treatments {#sec5dot1-ijms-19-03378}
-------------------------------------

Clear-cell RCC cell lines 786.0 and RC2 were cultured in Rosewell Memorial Park Institute (RMPI-1640) medium with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (PenStrep, Sigma-Aldrich, St. Louis, MO, USA) at 37 °C in an incubator with 5% CO~2~. Cells were routinely tested for mycoplasma contamination. Cells were seeded in T75 and/or T150 flasks, and were allowed to grow overnight. Cells were treated with MSA for 24 to 48 h, and were processed to isolate total RNA. Untreated control cells were maintained without treatment.

5.2. Animals {#sec5dot2-ijms-19-03378}
------------

Female athymic nude mice (Envigo, nu/nu, 20--25 g body weight), 8--12 weeks of age, were used for the tumor xenograft experiment as previously described \[[@B97-ijms-19-03378]\]. All studies were carried out as approved by the Institutional Roswell Park Comprehensive Cancer Center Animal Care and Use Committee (207M, 2009).

### Tumor Xenografts

Clear-cell RCC 786.0 cells were cultured in RMPI-1640 and transplanted into nude mice to establish xenografts. Tumors were harvested, and \~50 mg of non-necrotic tumor tissue was transplanted into nude mice and randomized to groups of 5--10 mice each. Treatment with drugs alone or in combination was started when tumors reached \~200 mg, and the tumor volume and response were measured as described previously \[[@B97-ijms-19-03378]\]. Drug toxicity was evaluated by measuring the weight loss of the mice biweekly.

5.3. Drugs {#sec5dot3-ijms-19-03378}
----------

MSC and SLM (Sigma-Aldrich, St. Louis, MO, USA) were given at 0.2 mg/kg for 35 days starting seven days prior to the start of drug treatment. Axitinib (AdooQ Bioscience, Irvine, CA, USA), sunitinib (LC laboratories, Woburn, MA, USA), and topotecan (Selleckchem, Houston, TX, USA) were administered orally at 25 mg/kg, 80 mg/kg, or 2 mg/kg five days per week for four weeks, either as a single drug or in combination. Avastin (Genentech, South San Francisco, CA, USA), was given at 5 mg/kg via intraperitoneal injection for five days/week for four weeks either by itself or in combination with selenium.

5.4. Total RNA Isolation from ccRCC Cells Treated with and without MSA {#sec5dot4-ijms-19-03378}
----------------------------------------------------------------------

Cells were treated with MSA for 24--48 h and processed for isolation of total RNA using Trizol reagent as per the instructions of the manufacturer (Invitrogen, Liverpool, NY, USA). RNA quantity and quality was measured using Nanodrop (Thermo-Fisher Scientific, Liverpool, NY, USA), and then used for microRNA microarray analysis and quantitative PCR analysis of microRNA.

5.5. Total RNA from ccRCC Patient Tumors and Their Matched Normal Tissues {#sec5dot5-ijms-19-03378}
-------------------------------------------------------------------------

Total RNA of de-identified ccRCC patient tumors and their matched normal kidneys were obtained from the RPCI Pathology core facility. RNA samples were isolated using Trizol reagent (Thermo-Fisher Scientific, Liverpool, NY, USA) from the non-necrotic tissues selected by the pathologist, and purity was determined before use for detecting microRNA expression by qRT-PCR.

5.6. Reverse Transcription (RT) and miRNA qPCR {#sec5dot6-ijms-19-03378}
----------------------------------------------

Complementary DNA (cDNA) was prepared using the following quantities of each reagent and RNA: 4 μL (20 ng) of RNA, 9 μL of H~2~O, 1 μL of Spike-In, 4 μL of reverse transcription (RT) buffer, and 2 μL of enzyme in a total volume of 20 μL. Immediately after the RT reaction was finished, a 1:80 dilution was made on the cDNA, and ROX was added. The reaction mix for qRT-PCR was prepared using 400 μL of SYBR^®^ Green Master Mix (Thermo-Fisher Scientific, Liverpool, NY, USA) and 320 μL of cDNA (from the above diluted RT reaction). Then, 9 µL of this mix was added to a 384-well plate pre-loaded with specific miR primers in triplicate using an electronic multichannel pipette. Plates were sealed with optical tape and shaken on a plate shaker for 30 s, before being centrifuged for one minute and run on the ABI7900 qPCR machine (Applied Biosystem, Foster City, CA, USA). Quantitative PCR machine cycling conditions and parameters were set exactly the same for every plate.

Normalization of Exiqon miRNA Panels (<http://www.exiqon.com/mirna-pcr-panels>) Excerpt from Exiqon Manual: Inter-Plate Calibrator (IPC). Since each assay was present only once on each plate, replicates were performed using separate plates. This raises the issue of run-to-run differences. To allow for simple inter-plate calibration, we designed a calibration assay with an accompanying template (annotated as UniSp3 or IPC in the plate layout files). Three wells were assigned for inter-plate calibration to provide triplicate values with the possibility for outlier removal. In each of these wells, both the primers and the DNA template were present, giving high reproducibility. The inter-plate calibrator requires only the addition of the SYBR^®^ Green master mix in order to give a signal and can, therefore, be used for quality control of each plate run.

GenEx Software (ver 6.1, Thermo-Fisher Scientific, Liverpool, NY, USA: <http://www.exiqon.com/qpcr-software>.

Plates were imported into the GenEx software (ver 6.1, Thermo-Fisher Scientific, Liverpool, NY, USA) and the IPCs (in triplicate on each plate) were used to normalize the plates helping to eliminate run-to-run variation when comparing multiple plates. All Ct values above 38 were set to 38 as the maximum value (this is arbitrary and may even be left blank to denoted non-amplification). All miRNAs were listed in an excel file regardless of whether or not they were expressed in the samples, with normalized Ct values for each sample. Data were represented as individual triplicate runs and as averages of triplicates (with outliers excluded). Expressions of miRNA were normalized to untreated controls, and fold changes with the selenium treatment were determined. In ccRCC patient tumors, microRNA expression was normalized to normal tissue and fold changes were determined.
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![Hypoxia-inducible factors (HIFs, '+' indicates presence and '−' means absence), vascular endothelial growth factor (VEGF), high-intensity thymidine phosphorylase (HTP), and programmed death ligand 1 (PD-L1) biomarker expression in clear-cell renal cell carcinoma (ccRCC) tumors. The data for HIFs and VEGF were generated by our laboratory \[[@B20-ijms-19-03378],[@B22-ijms-19-03378]\], while others are from published reports \[[@B13-ijms-19-03378],[@B63-ijms-19-03378]\].](ijms-19-03378-g001){#ijms-19-03378-f001}

![Constitutively expressed HIFs are selenium targets \[[@B20-ijms-19-03378],[@B32-ijms-19-03378]\]. Effects of methylseleninic acid (MSA), the active moiety of methylselenocysteine (MSC) or seleno-[l]{.smallcaps}-methionine (SLM), on the expression levels of constitutively expressed HIFs in RC2 and 786.0 renal cell carcinoma, and on HIF1α head and neck in FaDU, lung carcinoma, A549, and colorectal carcinoma cell lines. RC2 and 786.0 cells (adopted from Reference \[[@B20-ijms-19-03378]\]) were exposed to 10 μM MSA for 24 h, while other cells---FaDu (adopted from Reference \[[@B32-ijms-19-03378]\]), A549, and HT29---were exposed to 0.5% O~2~ for 24 h and treated with different MSA concentrations. Cells were lysed rapidly on ice and analyzed for HIF expression by Western blot \[[@B20-ijms-19-03378],[@B32-ijms-19-03378]\].](ijms-19-03378-g002){#ijms-19-03378-f002}

![MSC selectively stabilizes tumor vasculature \[[@B68-ijms-19-03378],[@B70-ijms-19-03378]\]. Effects of MSC treatment on the stabilization of tumor vasculature. Xenografts bearing FaDU tumors were treated orally with 10 mg/kg MSC daily for seven days, at which point the vascular maturation in tumor and normal liver tissues was assessed histologically \[[@B68-ijms-19-03378],[@B70-ijms-19-03378]\].](ijms-19-03378-g003){#ijms-19-03378-f003}

![Oncogenic and tumor-suppressor micro RNAs (miRNAs) expressed in ccRCC are selenium targets. Effects of MSA on the expression levels of oncogenic and tumor-suppressor miRNAs altered in RC2 cells expressing HIF1α: (**A**) microarray analysis of miRNAs regulated by the treatment of RC2 cells with 10.0 μM MSA for 24 h, and (**B**) selected miRNAs shortlisted for further analysis.](ijms-19-03378-g004){#ijms-19-03378-f004}

![Selected miRNAs expressed in primary ccRCC biopsies are also expressed in ccRCC cell lines and can be modulated by selenium. Modulation of miRNAs expressed in ccRCC patient tumor biopsies, and in RC2 and 786.0 cells lines treated with MSA**.** Quantitative RT-PCR analysis of selective hypoxia-regulated microRNA in human RCC patient tumors (*n* = 3), and in RC2 and 786.0 cells treated with MSA. MicroRNAs downregulated in human tumors (miR let7b and miR328) (**left panel**) found to be upregulated with MSA treatment in RC2 and 786.0 cells. MicroRNAs which were upregulated (**right panel**: miR106b, miR155, and miR210; **left panel**: miR185) in RCC patients were found to be downregulated with MSA treatment in RC2 and 786.0 cells. Log fold changes are shown compared to matched normal kidney tissues for patients and untreated RC2 and 786.0 cells.](ijms-19-03378-g005){#ijms-19-03378-f005}

![Antitumor activity of MSC in combination with irinotecan and docetaxel in nude mice bearing human head-and-neck cancer cells, FaDU and A253 (**A**), and radiation-treated A549 lung carcinoma (**B**). MSC was administered orally daily for seven days and concurrently with anticancer therapies administered on day seven \[[@B82-ijms-19-03378]\].](ijms-19-03378-g006){#ijms-19-03378-f006}

![Pretreatment of 786.0 xenografts expressing HIF2α with a nontoxic but molecularly effective dose of MSC sensitizes tumor cells to subsequent treatment with the combination of VEGF/VEGF receptor (VEGFR)-targeted agents and chemotherapy. Assessment of antitumor activity of MSC, SLM, Avastin, axitinib, sunitinib, and topotecan, administered individually to nude mice bearing 786.0 ccRCC tumors (**A**), and in combination with either MSC (**B**) or SLM (**C**), and in combination with axitinib (**D**). (**E**) Summary of the antitumor activity of MSC in sequential combination with anticancer therapies \[[@B83-ijms-19-03378]\].](ijms-19-03378-g007){#ijms-19-03378-f007}

!["Bench-to-bedside" therapeutic development of SLM from preclinical models to phase 1 and 2 clinical trials in patients with advanced clear-cell renal cell carcinoma (ccRCC).](ijms-19-03378-ch001){#ijms-19-03378-ch001}

![Schematic representation of targetable markers expressed in ccRCC. Methylselenocysteine (MSC) targets hypoxia-inducible factors (HIFs) and micro RNAs (miRNAs). Topotecan targets HIF synthesis, while tyrosine kinase inhibitors (TKIs) target vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) and 5-fluorouracil (5-FU) prodrugs are the substrate for activation by thymidine phosphorylase.](ijms-19-03378-ch002){#ijms-19-03378-ch002}
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###### 

Molecular profile of tumor biopsies.

  ------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------- ------------------------- -------------------------- --------------- --------------
  **Incidence of HIF-α and PHDs Protein Expression in Primary Human ccRCC, Head & neck (H/N) and Colorectal Cancer (CRC) Tumor Biopsies:**                                                                                                     
  **Tumors**                                                                                                                                 **HIF-1α**                   **HIF-2α**                **HIF-1α and/or HIF-2α**   **PHD2**        **PHD3**
  ccRCC                                                                                                                                      45% (40/88)                  78% (69/88)               92% (81/88)                35% (31/88)     0% (0/88)
  H/N                                                                                                                                        23% (40/173)                 16% (23/146)              38% (46/122)               86% (180/210)   21% (32/153)
  CRC                                                                                                                                        13% (8/62)                   15% (10/65)               26% (17/64)                90% (55/61)     50% (31/62)
                                                                                                                                             **VEGF(A)**                                                                                       
  **Tumors**                                                                                                                                 **Incidence of Positions**   **Average Immunoscope**                                              
  ccRCC                                                                                                                                      54% (48/88)                  2.3 (weak)                                                           
  H/N                                                                                                                                        79% (136/173)                4.24 (moderate)                                                      
  CRC                                                                                                                                        97% (60/62)                  5.68 (strong)                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------- ------------------------- -------------------------- --------------- --------------
